Advertisement

CID1551

A High Barrier to ResistanceThrough 96 Weeks1,3

CASES OF TREATMENT-EMERGENT RESISTANCE in virologically suppressed patients No patients in the DOVATO arm had confirmed virologic withdrawal (HIV-1 RNA ≥50 copies/mL followed by a second consecutive HIV-1 RNA ≥50 copies/mL)....

Read More

Studied in a Robust Phase 3 Clinical Trial: TANGO1

TRIAL DESIGN TANGO is an ongoing, Phase 3, randomized, noninferiority trial that randomized adults with HIV-1 RNA <50 copies/mL to switch to DOVATO or remain on a TAF-containing regimen Designed to evaluate the efficacy and...

Read More

PW PODCAST: COVID-19 & Children With Special Needs

During a recent PW Podcast episode, we spoke with Daniel A. Doherty, MD, PhD, Professor of Pediatrics and Research Affiliate for the Center on Human Development and Disability at the University of Washington. Following is a...

Read More

Amenorrhea & Bone Mineral Density in Women With HIV

Although previous studies indicate that HIV is a risk factor for missed menstrual periods, or amenorrhea, the downstream effects of amenorrhea and its associated hormonal dysregulation in these women remain poorly understood,...

Read More

Growing Acceptance of Undetectable = Untransmittable

Several studies have provided consistent data on the effectiveness of viral suppression on HIV transmission, collectively observing more than 100,000 condomless anal and vaginal sex acts that resulted in zero HIV transmissions...

Read More

Prevalence of C. difficile Carriage & Progression

More than 400,000 cases of Clostridioides difficile infection (CDI) and nearly 30,000 deaths from C. difficile-associated diarrhea are reported annually in the US. In the past, efforts to limit transmission have focused on...

Read More
  • 1
  • 2

For latest news and updates
Email-id is invalid